Table 4.

Baseline RBP4 levels predicts IR and MS components after 10-year follow-up

	Number of cases/total number of subjects	Model 1		Model 2		Model 3		Model 4
		OR/unit (95% CI)	P	OR/unit (95% CI)	P	OR/unit (95% CI)	P	OR/unit (95% CI)	P
IR (HOMA-IR ≥ 3.0)	73/352	1.42 (1.08–1.86)	0.011	1.44 (1.07-1.92)	0.015	1.36 (1.02–1.81)	0.039	1.35 (1.01–1.81)	0.049
Central obesity	152/352	1.20 (0.95–1.50)	0.125	1.25 (0.99-1.57)	0.065	1.00 (0.74–1.35)	0.979	1.00 (0.74–1.34)	0.974
Elevated blood pressure	75/352	1.38 (1.07–1.76)	0.012	1.46 (1.08-1.99)	0.015	1.38 (1.01–1.91)	0.049	1.33 (1.01–1.76)	0.046
Reduced HDL-C	58/352	1.08 (0.80–1.47)	0.612	1.05 (0.77-1.45)	0.756	1.09 (0.78–1.52)	0.609	1.04 (0.75–1.43)	0.830
Elevated TG	61/352	1.83 (1.40–2.41)	< 0.001	1.76 (1.33-2.33)	< 0.001	1.54 (1.14–2.07)	0.004	1.70 (1.28–2.26)	< 0.001
Hyperglycemia	44/352	1.49 (1.11–1.99)	0.008	1.48 (1.10-1.98)	0.009	1.55 (1.14–2.09)	0.005	1.51 (1.12–2.03)	0.007

OR indicates odds ratio for per 10 μg/ml (approximately 1 SD) increase in baseline RBP4 levels

BMI body mass index, HOMA-IR homeostatic model assessment of insulin resistance, IR insulin resistance, TG triglycerides, HDL-C high-density lipoprotein cholesterol, MS metabolic syndrome

Model 1: adjusted for age, gender and pubertal stage at baseline

Model 2: Model 1 + additionally adjusted with physical activity, dietary score, and baseline BMI (except central obesity model)

Model 3: Model 2 + additionally adjusted with levels of the individual components at baseline

Model 4: Model 1 + additionally adjusted with adiponectin, leptin levels and BMI at baseline